Radioimaging of the cancer cells allowing for a more clear diagnosis without significant adverse health effects.

Summary

Existing cancer therapies include surgery, chemotherapy and
radiation therapy. The most major drawbacks to these therapies are
multidrug resistance, neurotoxicity, and nephrotoxicity. This
invention overcomes these disadvantages by using a radiolabeled
5'-iodo-2'-deoxyuridine (125IUdR) conjugated to
4-dihydrotestosterone (DHT) and thereby targeting the androgen
receptor. The 125IUdR is transported via the sex hormone binding
globulin to the rapidly growing and dividing cancer cells with the
androgen receptors present and is then transported into the cancer
cell. Once inside the cell, the cell cycle dependent therapeutic
agent is incorporated into the DNA and the cytotoxic effect is
induced. This invention has the added benefit of radioimaging of
the cancer cells allowing for a more clear diagnosis. These
conjugates are administered safely in long term therapies and do
not produce significant adverse health effects.

Market Value

Has the added benefit of radioimaging of the cancer cells allowing
for a more clear diagnosis without significant adverse health effects.

Features and Benefits

• Targeted drug delivery
• Used in tumor imaging

Early Stage

Patent Status: Issued 7,220,730 and 5,468,853

(TID 01)

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with University of Nebraska Medical Center.